Veru Inc. (VERU) 10-Year Financial Performance & Capital Metrics

VERU • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutVeru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.Show more

Revenue $0 -100.0%
EBITDA $9M +124.7%
Net Income -$23M +39.9%
EPS (Diluted) -1.55 +44.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -89.74% +38.3%
ROIC 50.54% +141.7%
Debt/Equity 0.17 -60.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-52.76%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM38.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM43.44%

ROCE

10Y Avg-37.88%

5Y Avg-52.5%

3Y Avg-70.43%

Latest25.69%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales/Revenue+	22.13M	13.66M	15.86M	31.8M	42.59M	61.26M	39.35M	16.3M	16.89M	0
Revenue Growth %	-0.32%	-0.38%	0.16%	1%	0.34%	0.44%	-0.36%	-0.59%	0.04%	-1%
Cost of Goods Sold+	8.78M	6.64M	7.08M	10.15M	11.81M	13.33M	8.76M	8.73M	11.03M	0
COGS % of Revenue	0.4%	0.49%	0.45%	0.32%	0.28%	0.22%	0.22%	0.54%	0.65%	-
Gross Profit+	13.35M	7.02M	8.78M	21.66M	30.79M	47.93M	30.59M	7.57M	5.85M	0
Gross Margin %	0.6%	0.51%	0.55%	0.68%	0.72%	0.78%	0.78%	0.46%	0.35%	-
Gross Profit Growth %	-0.3%	-0.47%	0.25%	1.47%	0.42%	0.56%	-0.36%	-0.75%	-0.23%	-1%
Operating Expenses+	10.33M	14.58M	29.65M	28.09M	45.53M	53.36M	113.81M	101.35M	42.77M	35.53M
OpEx % of Revenue	0.47%	1.07%	1.87%	0.88%	1.07%	0.87%	2.89%	6.22%	2.53%	-
Selling, General & Admin	8.75M	11.07M	14.82M	14.35M	14.5M	20.67M	43.17M	48.06M	31.18M	19.94M
SG&A % of Revenue	0.4%	0.81%	0.93%	0.45%	0.34%	0.34%	1.1%	2.95%	1.85%	-
Research & Development	99.39K	3.5M	10.85M	13.74M	16.94M	32.69M	70.65M	51.2M	12.81M	15.59M
R&D % of Revenue	0%	0.26%	0.68%	0.43%	0.4%	0.53%	1.8%	3.14%	0.76%	-
Other Operating Expenses	9.2M	0	-2.2M	0	14.1M	0	0	2.09M	-1.22M	0
Operating Income+	3.02M	-8.49M	-20.87M	-6.44M	-14.75M	12.97M	-83.22M	-93.78M	-36.92M	9.07M
Operating Margin %	0.14%	-0.62%	-1.32%	-0.2%	-0.35%	0.21%	-2.11%	-5.75%	-2.19%	-
Operating Income Growth %	-0.54%	-3.81%	-1.46%	0.69%	-1.29%	1.88%	-7.42%	-0.13%	0.61%	1.25%
EBITDA+	3.44M	-8.01M	-20.42M	-5.96M	-13.96M	13.57M	-83.01M	-93.51M	-36.65M	9.07M
EBITDA Margin %	0.16%	-0.59%	-1.29%	-0.19%	-0.33%	0.22%	-2.11%	-5.74%	-2.17%	-
EBITDA Growth %	-0.52%	-3.33%	-1.55%	0.71%	-1.34%	1.97%	-7.12%	-0.13%	0.61%	1.25%
D&A (Non-Cash Add-back)	422.87K	481.01K	452.05K	471.42K	783.64K	593.87K	209.59K	269.87K	268.18K	0
EBIT	4.5M	-8.6M	-20.12M	-7.62M	-15.43M	9.15M	-79.44M	-90.25M	-36.47M	0
Net Interest Income+	-57.06K	0	-2.95M	-4.71M	-4.62M	-4.89M	-4.37M	-2.43M	-607.47K	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	3.32M	2.04M	2.95M	4.71M	4.62M	4.89M	4.37M	2.43M	607.47K	0
Other Income/Expense	-204.6K	-108.38K	-2.2M	-5.89M	-5.31M	-8.71M	-580.66K	1.11M	-160.93K	-31.8M
Pretax Income+	2.81M	-8.6M	-23.07M	-12.32M	-20.05M	4.27M	-83.8M	-92.67M	-37.08M	-22.73M
Pretax Margin %	0.13%	-0.63%	-1.45%	-0.39%	-0.47%	0.07%	-2.13%	-5.69%	-2.2%	-
Income Tax+	2.47M	-1.99M	866.1K	-303.93K	-1.08M	-3.13M	236.4K	480.21K	725.1K	0
Effective Tax Rate %	0.12%	0.77%	1.04%	0.98%	0.95%	1.73%	1%	1.01%	1.02%	1%
Net Income+	344.73K	-6.61M	-23.94M	-12.02M	-18.97M	7.39M	-83.78M	-93.15M	-37.8M	-22.73M
Net Margin %	0.02%	-0.48%	-1.51%	-0.38%	-0.45%	0.12%	-2.13%	-5.72%	-2.24%	-
Net Income Growth %	-0.92%	-20.18%	-2.62%	0.5%	-0.58%	1.39%	-12.33%	-0.11%	0.59%	0.4%
Net Income (Continuing)	344.73K	-6.61M	-23.94M	-12.02M	-18.97M	7.39M	-84.04M	-93.15M	-37.8M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.10	-2.48	-4.44	-1.90	-2.84	0.88	-10.49	-10.96	-2.80	-1.55
EPS Growth %	-0.93%	-25.84%	-0.79%	0.57%	-0.49%	1.31%	-12.92%	-0.04%	0.74%	0.45%
EPS (Basic)	0.10	-2.48	-4.44	-1.90	-2.84	0.97	-10.49	-10.96	-2.80	-1.55
Diluted Shares Outstanding	2.89M	3.46M	5.39M	6.33M	6.68M	8.38M	8.01M	8.5M	13.49M	14.65M
Basic Shares Outstanding	2.87M	3.46M	5.39M	6.33M	6.68M	7.63M	8.01M	8.5M	13.49M	14.65M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Current Assets+	18.31M	10.3M	11.18M	16.81M	27.01M	151.75M	104M	22.93M	35.22M	18.92M
Cash & Short-Term Investments	2.39M	3.28M	3.76M	6.3M	13.59M	122.36M	80.19M	9.63M	24.92M	15.79M
Cash Only	2.39M	3.28M	3.76M	6.3M	13.59M	122.36M	80.19M	9.63M	24.92M	15.79M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	10.78M	3.42M	3.97M	5.02M	5.23M	13.79M	3.55M	4.51M	3.96M	0
Days Sales Outstanding	177.78	91.38	91.4	57.63	44.8	82.19	32.93	100.93	85.6	-
Inventory	2.49M	2.77M	2.3M	3.65M	6.7M	5.57M	8.62M	6.7M	4.14M	0
Days Inventory Outstanding	103.65	152.24	118.64	131.21	207.28	152.61	359	279.97	137.11	-
Other Current Assets	2.02M	0	0	0	613.27K	850.89K	1.96M	1.1M	1.78M	3.12M
Total Non-Current Assets+	20.31M	45.01M	37.27M	36.82M	24.53M	26.39M	31.36M	27.09M	25.2M	10.92M
Property, Plant & Equipment	825.09K	555.54K	404.55K	351.89K	1.67M	1.56M	5.97M	5.99M	4.85M	3.11M
Fixed Asset Turnover	26.82x	24.58x	39.21x	90.38x	25.58x	39.21x	6.59x	2.72x	3.48x	-
Goodwill	0	6.88M	6.88M	6.88M	6.88M	6.88M	6.88M	6.88M	6.88M	6.88M
Intangible Assets	0	20.75M	20.48M	20.17M	5.75M	4.05M	3.98M	5.95K	0	0
Long-Term Investments	7.84M	7.84M	0	0	0	-1.56M	0	0	0	0
Other Non-Current Assets	8.03M	156.43K	965.15K	988.87K	766.12K	2.44M	1.56M	1.51M	1.13M	930.85K
Total Assets+	38.62M	55.31M	48.45M	53.63M	51.54M	178.15M	135.36M	50.02M	60.42M	29.84M
Asset Turnover	0.57x	0.25x	0.33x	0.59x	0.83x	0.34x	0.29x	0.33x	0.28x	-
Asset Growth %	0.03%	0.43%	-0.12%	0.11%	-0.04%	2.46%	-0.24%	-0.63%	0.21%	-0.51%
Total Current Liabilities+	3.35M	5.49M	13.55M	14.02M	14.73M	15.77M	38.71M	17.81M	11.87M	7.79M
Accounts Payable	701.03K	2.69M	3.23M	3.12M	2.81M	3.41M	22M	12.93M	3.04M	3.12M
Days Payables Outstanding	29.15	147.72	166.27	112.41	86.96	93.35	916.5	540.59	100.47	-
Short-Term Debt	0	0	6.69M	5.39M	6.94M	3.24M	1.17M	864.62K	1.03M	758.95K
Deferred Revenue (Current)	0	1000K	202.45K	249K	6K	132K	0	105K	400K	0
Other Current Liabilities	0	1.01M	191.16K	0	0	0	5.99M	100K	0	7.03M
Current Ratio	5.47x	1.88x	0.83x	1.20x	1.83x	9.62x	2.69x	1.29x	2.97x	2.43x
Quick Ratio	4.73x	1.37x	0.66x	0.94x	1.38x	9.27x	2.46x	0.91x	2.62x	2.43x
Cash Conversion Cycle	252.28	95.9	43.78	76.43	165.11	141.45	-524.56	-159.68	122.24	-
Total Non-Current Liabilities+	1.34M	1.37M	5.42M	7.28M	6.71M	10.09M	13.85M	12.53M	16.23M	3.72M
Long-Term Debt	0	0	4.46M	6.73M	5.62M	9.4M	9.66M	8.87M	8.85M	2.36M
Capital Lease Obligations	0	0	0	0	998.02K	609.92K	4.09M	3.63M	2.92M	0
Deferred Tax Liabilities	110.07K	0	844.76K	296.61K	74.72K	63.43K	81.07K	451.16K	0	0
Other Non-Current Liabilities	1.23M	1.4M	118.16K	247.15K	14.98K	14.99K	18.58K	29.95K	4.46M	1.36M
Total Liabilities	4.69M	6.85M	18.97M	21.3M	21.43M	25.85M	52.56M	30.34M	28.1M	11.5M
Total Debt+	0	0	11.15M	12.12M	14.14M	13.74M	15.88M	14.41M	13.86M	3.12M
Net Debt	-2.39M	-3.28M	7.39M	5.82M	547.57K	-108.61M	-64.31M	4.78M	-11.05M	-12.68M
Debt / Equity	-	-	0.38x	0.37x	0.47x	0.09x	0.19x	0.73x	0.43x	0.17x
Debt / EBITDA	-	-	-	-	-	1.01x	-	-	-	0.34x
Net Debt / EBITDA	-0.69x	-	-	-	-	-8.01x	-	-	-	-1.40x
Interest Coverage	0.91x	-4.16x	-7.07x	-1.37x	-3.19x	2.66x	-19.05x	-38.64x	-60.77x	-
Total Equity+	33.93M	48.45M	29.48M	32.33M	30.11M	152.29M	82.8M	19.68M	32.32M	18.33M
Equity Growth %	0.02%	0.43%	-0.39%	0.1%	-0.07%	4.06%	-0.46%	-0.76%	0.64%	-0.43%
Book Value per Share	11.73	13.99	5.47	5.11	4.51	18.17	10.33	2.32	2.40	1.25
Total Shareholders' Equity	33.93M	48.45M	29.48M	32.33M	30.11M	152.29M	82.8M	19.68M	32.32M	18.33M
Common Stock	312.74K	553.92K	574.69K	672.22K	720.47K	821.53K	826.93K	939.66K	1.49M	148.69K
Retained Earnings	-27.65M	-34.26M	-58.2M	-70.22M	-89.19M	-81.8M	-163.62M	-256.77M	-294.57M	-317.3M
Treasury Stock	-7.81M	-7.81M	-7.81M	-7.81M	-7.81M	-7.81M	-7.81M	-7.81M	-7.81M	0
Accumulated OCI	-581.52K	-581.52K	-581.52K	-581.52K	-581.52K	-581.52K	-581.52K	-581.52K	-581.52K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Cash from Operations+	-1.71M	982.89K	-11.55M	-5.49M	-1.93M	-15.57M	-47.51M	-88.01M	-21.68M	-30.04M
Operating CF Margin %	-0.08%	0.07%	-0.73%	-0.17%	-0.05%	-0.25%	-1.21%	-5.4%	-1.28%	-
Operating CF Growth %	-0.11%	1.57%	-12.75%	0.52%	0.65%	-7.07%	-2.05%	-0.85%	0.75%	-0.39%
Net Income	344.73K	-6.61M	-23.94M	-12.02M	-18.97M	7.39M	-83.78M	-93.15M	-37.8M	-22.73M
Depreciation & Amortization	423.57K	481.01K	452.05K	471.42K	462.74K	211.39K	209.59K	269.87K	268.18K	152.1K
Stock-Based Compensation	499.87K	756.27K	1.64M	1.91M	2.65M	5.05M	11.24M	17.92M	13.64M	8.1M
Deferred Taxes	2.05M	-2.26M	630.15K	-438.06K	-1.26M	-3.57M	76.21K	177.5K	367.18K	-1.92K
Other Non-Cash Items	-8.63K	962.1K	6.13M	6.16M	19.54M	-17.38M	-1.14M	1.92M	1.62M	-15.57M
Working Capital Changes	-5.03M	7.65M	3.54M	-1.56M	-4.35M	-7.28M	25.88M	-15.15M	222.49K	0
Change in Receivables	-4.52M	7.23M	1.87M	-1.35M	-87.79K	-3.56M	4.54M	-4.15M	546.2K	-657.25K
Change in Inventory	-738.83K	-479.42K	375.04K	-1.45M	-3.3M	546.38K	-3.13M	648.63K	986.11K	863.93K
Change in Payables	-376.31K	897.47K	495.97K	-56.94K	-312.08K	597.1K	18.59M	-7.43M	-5.43M	-2.76M
Cash from Investing+	-6.37K	-90.37K	-50.65K	-108.52K	-105.76K	14.62M	4.27M	6.33M	146.21K	25.14M
Capital Expenditures	-6.37K	-133.49K	-50.65K	-108.52K	-105.76K	-376.65K	-733.05K	-665.7K	-158.32K	-1.08K
CapEx % of Revenue	0%	0.01%	0%	0%	0%	0.01%	0.02%	0.04%	0.01%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	7M	304.54K	24.75M
Cash from Financing+	0	0	12.08M	8.13M	9.33M	109.72M	1.07M	11.11M	36.83M	-4.22M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	2.72M	3.66M	0	1.64M	0	4.97M	1.66M	-4.22M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.72M	849.4K	-11.6M	-5.59M	-2.04M	-15.95M	-48.24M	-88.68M	-21.84M	-30.04M
FCF Margin %	-0.08%	0.06%	-0.73%	-0.18%	-0.05%	-0.26%	-1.23%	-5.44%	-1.29%	-
FCF Growth %	-0.02%	1.49%	-14.65%	0.52%	0.64%	-6.83%	-2.02%	-0.84%	0.75%	-0.38%
FCF per Share	-0.59	0.25	-2.15	-0.88	-0.30	-1.90	-6.02	-10.44	-1.62	-2.05
FCF Conversion (FCF/Net Income)	-4.97x	-0.15x	0.48x	0.46x	0.10x	-2.11x	0.57x	0.94x	0.57x	1.32x
Interest Paid	0	0	0	0	314.5K	8.48M	2.62M	554.82K	704.6K	0
Taxes Paid	0	0	222.22K	303.58K	362.06K	248.75K	422.13K	247.36K	368.82K	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	1.03%	-16.05%	-61.43%	-38.88%	-60.77%	8.11%	-71.27%	-181.8%	-145.4%	-89.74%
Return on Invested Capital (ROIC)	7.47%	-16.61%	-38.16%	-12.87%	-32.14%	26.18%	-200.83%	-327.6%	-121.11%	50.54%
Gross Margin	60.33%	51.4%	55.36%	68.1%	72.28%	78.24%	77.73%	46.43%	34.67%	-
Net Margin	1.56%	-48.42%	-150.89%	-37.79%	-44.55%	12.07%	-212.88%	-571.6%	-223.86%	-
Debt / Equity	-	-	0.38x	0.37x	0.47x	0.09x	0.19x	0.73x	0.43x	0.17x
Interest Coverage	0.91x	-4.16x	-7.07x	-1.37x	-3.19x	2.66x	-19.05x	-38.64x	-60.77x	-
FCF Conversion	-4.97x	-0.15x	0.48x	0.46x	0.10x	-2.11x	0.57x	0.94x	0.57x	1.32x
Revenue Growth	-32.13%	-38.29%	16.18%	100.47%	33.92%	43.83%	-35.76%	-58.59%	3.62%	-100%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Global public health sector	-	-	-	-	-	-	-	-	-	14.49M
Global public health sector Growth	-	-	-	-	-	-	-	-	-	-
U.S. prescription channel	-	-	-	-	-	-	-	-	-	2.4M
U.S. prescription channel Growth	-	-	-	-	-	-	-	-	-	-
Other Products	-	-	-	-	-	-	-	2.42K	13.01K	-
Other Products Growth	-	-	-	-	-	-	-	-	438.84%	-
Preboost	-	-	-	-	884.02K	2.04M	862.83K	-	-	-
Preboost Growth	-	-	-	-	-	130.23%	-57.61%	-	-	-
U	-	-	-	5.22M	-	-	-	-	-	-
U Growth	-	-	-	-	-	-	-	-	-	-
Other Countries	-	-	-	4.52M	-	-	-	-	-	-
Other Countries Growth	-	-	-	-	-	-	-	-	-	-
Z	-	-	-	2.16M	-	-	-	-	-	-
Z Growth	-	-	-	-	-	-	-	-	-	-
K	-	-	-	1.01M	-	-	-	-	-	-
K Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	-	-	-	5.35M
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-
Other Geographical Areas	-	-	-	-	-	-	-	-	-	4.7M
Other Geographical Areas Growth	-	-	-	-	-	-	-	-	-	-
BRAZIL	-	-	-	-	-	-	-	-	-	2.76M
BRAZIL Growth	-	-	-	-	-	-	-	-	-	-
MOZAMBIQUE	-	-	-	-	-	-	-	-	-	2.17M
MOZAMBIQUE Growth	-	-	-	-	-	-	-	-	-	-
SOUTH AFRICA	-	-	-	-	-	-	-	-	-	1.9M
SOUTH AFRICA Growth	-	-	-	-	-	-	-	-	-	-
U	2.03M	2.46M	1.29M	5.22M	17.26M	30.34M	48.94M	31.43M	-	-
U Growth	-	21.44%	-47.73%	305.28%	230.65%	75.77%	61.31%	-35.78%	-	-
Other Countries	10.71M	9.23M	6.02M	4.52M	14.54M	12.25M	12.32M	7.92M	-	-
Other Countries Growth	-	-13.77%	-34.78%	-24.98%	221.89%	-15.74%	0.54%	-35.68%	-	-
Z	2.7M	3.31M	2.23M	2.16M	-	-	-	-	-	-
Z Growth	-	22.59%	-32.62%	-3.05%	-	-	-	-	-	-
K	-	-	-	1.01M	-	-	-	-	-	-
K Growth	-	-	-	-	-	-	-	-	-	-
M	-	-	1.43M	-	-	-	-	-	-	-
M Growth	-	-	-	-	-	-	-	-	-	-
C	-	-	891K	-	-	-	-	-	-	-
C Growth	-	-	-	-	-	-	-	-	-	-
N	-	-	846K	-	-	-	-	-	-	-
N Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Veru Inc. (VERU) reported $6.7M in revenue for fiscal year 2025. This represents a 81% decrease from $35.0M in 2012.

Veru Inc. (VERU) saw revenue decline by 100.0% over the past year.

Veru Inc. (VERU) reported a net loss of $32.7M for fiscal year 2025.

Dividend & Returns

Veru Inc. (VERU) has a return on equity (ROE) of -89.7%. Negative ROE indicates the company is unprofitable.

Veru Inc. (VERU) had negative free cash flow of $29.0M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Veru Inc. (VERU) 10-Year Financial Performance & Capital Metrics

VERU • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0 -100.0%
EBITDA $9M +124.7%
Net Income -$23M +39.9%
EPS (Diluted) -1.55 +44.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -89.74% +38.3%
ROIC 50.54% +141.7%
Debt/Equity 0.17 -60.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-52.76%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM38.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM43.44%

ROCE

10Y Avg-37.88%

5Y Avg-52.5%

3Y Avg-70.43%

Latest25.69%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales/Revenue+	22.13M	13.66M	15.86M	31.8M	42.59M	61.26M	39.35M	16.3M	16.89M	0
Revenue Growth %	-0.32%	-0.38%	0.16%	1%	0.34%	0.44%	-0.36%	-0.59%	0.04%	-1%
Cost of Goods Sold+	8.78M	6.64M	7.08M	10.15M	11.81M	13.33M	8.76M	8.73M	11.03M	0
COGS % of Revenue	0.4%	0.49%	0.45%	0.32%	0.28%	0.22%	0.22%	0.54%	0.65%	-
Gross Profit+	13.35M	7.02M	8.78M	21.66M	30.79M	47.93M	30.59M	7.57M	5.85M	0
Gross Margin %	0.6%	0.51%	0.55%	0.68%	0.72%	0.78%	0.78%	0.46%	0.35%	-
Gross Profit Growth %	-0.3%	-0.47%	0.25%	1.47%	0.42%	0.56%	-0.36%	-0.75%	-0.23%	-1%
Operating Expenses+	10.33M	14.58M	29.65M	28.09M	45.53M	53.36M	113.81M	101.35M	42.77M	35.53M
OpEx % of Revenue	0.47%	1.07%	1.87%	0.88%	1.07%	0.87%	2.89%	6.22%	2.53%	-
Selling, General & Admin	8.75M	11.07M	14.82M	14.35M	14.5M	20.67M	43.17M	48.06M	31.18M	19.94M
SG&A % of Revenue	0.4%	0.81%	0.93%	0.45%	0.34%	0.34%	1.1%	2.95%	1.85%	-
Research & Development	99.39K	3.5M	10.85M	13.74M	16.94M	32.69M	70.65M	51.2M	12.81M	15.59M
R&D % of Revenue	0%	0.26%	0.68%	0.43%	0.4%	0.53%	1.8%	3.14%	0.76%	-
Other Operating Expenses	9.2M	0	-2.2M	0	14.1M	0	0	2.09M	-1.22M	0
Operating Income+	3.02M	-8.49M	-20.87M	-6.44M	-14.75M	12.97M	-83.22M	-93.78M	-36.92M	9.07M
Operating Margin %	0.14%	-0.62%	-1.32%	-0.2%	-0.35%	0.21%	-2.11%	-5.75%	-2.19%	-
Operating Income Growth %	-0.54%	-3.81%	-1.46%	0.69%	-1.29%	1.88%	-7.42%	-0.13%	0.61%	1.25%
EBITDA+	3.44M	-8.01M	-20.42M	-5.96M	-13.96M	13.57M	-83.01M	-93.51M	-36.65M	9.07M
EBITDA Margin %	0.16%	-0.59%	-1.29%	-0.19%	-0.33%	0.22%	-2.11%	-5.74%	-2.17%	-
EBITDA Growth %	-0.52%	-3.33%	-1.55%	0.71%	-1.34%	1.97%	-7.12%	-0.13%	0.61%	1.25%
D&A (Non-Cash Add-back)	422.87K	481.01K	452.05K	471.42K	783.64K	593.87K	209.59K	269.87K	268.18K	0
EBIT	4.5M	-8.6M	-20.12M	-7.62M	-15.43M	9.15M	-79.44M	-90.25M	-36.47M	0
Net Interest Income+	-57.06K	0	-2.95M	-4.71M	-4.62M	-4.89M	-4.37M	-2.43M	-607.47K	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	3.32M	2.04M	2.95M	4.71M	4.62M	4.89M	4.37M	2.43M	607.47K	0
Other Income/Expense	-204.6K	-108.38K	-2.2M	-5.89M	-5.31M	-8.71M	-580.66K	1.11M	-160.93K	-31.8M
Pretax Income+	2.81M	-8.6M	-23.07M	-12.32M	-20.05M	4.27M	-83.8M	-92.67M	-37.08M	-22.73M
Pretax Margin %	0.13%	-0.63%	-1.45%	-0.39%	-0.47%	0.07%	-2.13%	-5.69%	-2.2%	-
Income Tax+	2.47M	-1.99M	866.1K	-303.93K	-1.08M	-3.13M	236.4K	480.21K	725.1K	0
Effective Tax Rate %	0.12%	0.77%	1.04%	0.98%	0.95%	1.73%	1%	1.01%	1.02%	1%
Net Income+	344.73K	-6.61M	-23.94M	-12.02M	-18.97M	7.39M	-83.78M	-93.15M	-37.8M	-22.73M
Net Margin %	0.02%	-0.48%	-1.51%	-0.38%	-0.45%	0.12%	-2.13%	-5.72%	-2.24%	-
Net Income Growth %	-0.92%	-20.18%	-2.62%	0.5%	-0.58%	1.39%	-12.33%	-0.11%	0.59%	0.4%
Net Income (Continuing)	344.73K	-6.61M	-23.94M	-12.02M	-18.97M	7.39M	-84.04M	-93.15M	-37.8M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.10	-2.48	-4.44	-1.90	-2.84	0.88	-10.49	-10.96	-2.80	-1.55
EPS Growth %	-0.93%	-25.84%	-0.79%	0.57%	-0.49%	1.31%	-12.92%	-0.04%	0.74%	0.45%
EPS (Basic)	0.10	-2.48	-4.44	-1.90	-2.84	0.97	-10.49	-10.96	-2.80	-1.55
Diluted Shares Outstanding	2.89M	3.46M	5.39M	6.33M	6.68M	8.38M	8.01M	8.5M	13.49M	14.65M
Basic Shares Outstanding	2.87M	3.46M	5.39M	6.33M	6.68M	7.63M	8.01M	8.5M	13.49M	14.65M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Current Assets+	18.31M	10.3M	11.18M	16.81M	27.01M	151.75M	104M	22.93M	35.22M	18.92M
Cash & Short-Term Investments	2.39M	3.28M	3.76M	6.3M	13.59M	122.36M	80.19M	9.63M	24.92M	15.79M
Cash Only	2.39M	3.28M	3.76M	6.3M	13.59M	122.36M	80.19M	9.63M	24.92M	15.79M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	10.78M	3.42M	3.97M	5.02M	5.23M	13.79M	3.55M	4.51M	3.96M	0
Days Sales Outstanding	177.78	91.38	91.4	57.63	44.8	82.19	32.93	100.93	85.6	-
Inventory	2.49M	2.77M	2.3M	3.65M	6.7M	5.57M	8.62M	6.7M	4.14M	0
Days Inventory Outstanding	103.65	152.24	118.64	131.21	207.28	152.61	359	279.97	137.11	-
Other Current Assets	2.02M	0	0	0	613.27K	850.89K	1.96M	1.1M	1.78M	3.12M
Total Non-Current Assets+	20.31M	45.01M	37.27M	36.82M	24.53M	26.39M	31.36M	27.09M	25.2M	10.92M
Property, Plant & Equipment	825.09K	555.54K	404.55K	351.89K	1.67M	1.56M	5.97M	5.99M	4.85M	3.11M
Fixed Asset Turnover	26.82x	24.58x	39.21x	90.38x	25.58x	39.21x	6.59x	2.72x	3.48x	-
Goodwill	0	6.88M	6.88M	6.88M	6.88M	6.88M	6.88M	6.88M	6.88M	6.88M
Intangible Assets	0	20.75M	20.48M	20.17M	5.75M	4.05M	3.98M	5.95K	0	0
Long-Term Investments	7.84M	7.84M	0	0	0	-1.56M	0	0	0	0
Other Non-Current Assets	8.03M	156.43K	965.15K	988.87K	766.12K	2.44M	1.56M	1.51M	1.13M	930.85K
Total Assets+	38.62M	55.31M	48.45M	53.63M	51.54M	178.15M	135.36M	50.02M	60.42M	29.84M
Asset Turnover	0.57x	0.25x	0.33x	0.59x	0.83x	0.34x	0.29x	0.33x	0.28x	-
Asset Growth %	0.03%	0.43%	-0.12%	0.11%	-0.04%	2.46%	-0.24%	-0.63%	0.21%	-0.51%
Total Current Liabilities+	3.35M	5.49M	13.55M	14.02M	14.73M	15.77M	38.71M	17.81M	11.87M	7.79M
Accounts Payable	701.03K	2.69M	3.23M	3.12M	2.81M	3.41M	22M	12.93M	3.04M	3.12M
Days Payables Outstanding	29.15	147.72	166.27	112.41	86.96	93.35	916.5	540.59	100.47	-
Short-Term Debt	0	0	6.69M	5.39M	6.94M	3.24M	1.17M	864.62K	1.03M	758.95K
Deferred Revenue (Current)	0	1000K	202.45K	249K	6K	132K	0	105K	400K	0
Other Current Liabilities	0	1.01M	191.16K	0	0	0	5.99M	100K	0	7.03M
Current Ratio	5.47x	1.88x	0.83x	1.20x	1.83x	9.62x	2.69x	1.29x	2.97x	2.43x
Quick Ratio	4.73x	1.37x	0.66x	0.94x	1.38x	9.27x	2.46x	0.91x	2.62x	2.43x
Cash Conversion Cycle	252.28	95.9	43.78	76.43	165.11	141.45	-524.56	-159.68	122.24	-
Total Non-Current Liabilities+	1.34M	1.37M	5.42M	7.28M	6.71M	10.09M	13.85M	12.53M	16.23M	3.72M
Long-Term Debt	0	0	4.46M	6.73M	5.62M	9.4M	9.66M	8.87M	8.85M	2.36M
Capital Lease Obligations	0	0	0	0	998.02K	609.92K	4.09M	3.63M	2.92M	0
Deferred Tax Liabilities	110.07K	0	844.76K	296.61K	74.72K	63.43K	81.07K	451.16K	0	0
Other Non-Current Liabilities	1.23M	1.4M	118.16K	247.15K	14.98K	14.99K	18.58K	29.95K	4.46M	1.36M
Total Liabilities	4.69M	6.85M	18.97M	21.3M	21.43M	25.85M	52.56M	30.34M	28.1M	11.5M
Total Debt+	0	0	11.15M	12.12M	14.14M	13.74M	15.88M	14.41M	13.86M	3.12M
Net Debt	-2.39M	-3.28M	7.39M	5.82M	547.57K	-108.61M	-64.31M	4.78M	-11.05M	-12.68M
Debt / Equity	-	-	0.38x	0.37x	0.47x	0.09x	0.19x	0.73x	0.43x	0.17x
Debt / EBITDA	-	-	-	-	-	1.01x	-	-	-	0.34x
Net Debt / EBITDA	-0.69x	-	-	-	-	-8.01x	-	-	-	-1.40x
Interest Coverage	0.91x	-4.16x	-7.07x	-1.37x	-3.19x	2.66x	-19.05x	-38.64x	-60.77x	-
Total Equity+	33.93M	48.45M	29.48M	32.33M	30.11M	152.29M	82.8M	19.68M	32.32M	18.33M
Equity Growth %	0.02%	0.43%	-0.39%	0.1%	-0.07%	4.06%	-0.46%	-0.76%	0.64%	-0.43%
Book Value per Share	11.73	13.99	5.47	5.11	4.51	18.17	10.33	2.32	2.40	1.25
Total Shareholders' Equity	33.93M	48.45M	29.48M	32.33M	30.11M	152.29M	82.8M	19.68M	32.32M	18.33M
Common Stock	312.74K	553.92K	574.69K	672.22K	720.47K	821.53K	826.93K	939.66K	1.49M	148.69K
Retained Earnings	-27.65M	-34.26M	-58.2M	-70.22M	-89.19M	-81.8M	-163.62M	-256.77M	-294.57M	-317.3M
Treasury Stock	-7.81M	-7.81M	-7.81M	-7.81M	-7.81M	-7.81M	-7.81M	-7.81M	-7.81M	0
Accumulated OCI	-581.52K	-581.52K	-581.52K	-581.52K	-581.52K	-581.52K	-581.52K	-581.52K	-581.52K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Cash from Operations+	-1.71M	982.89K	-11.55M	-5.49M	-1.93M	-15.57M	-47.51M	-88.01M	-21.68M	-30.04M
Operating CF Margin %	-0.08%	0.07%	-0.73%	-0.17%	-0.05%	-0.25%	-1.21%	-5.4%	-1.28%	-
Operating CF Growth %	-0.11%	1.57%	-12.75%	0.52%	0.65%	-7.07%	-2.05%	-0.85%	0.75%	-0.39%
Net Income	344.73K	-6.61M	-23.94M	-12.02M	-18.97M	7.39M	-83.78M	-93.15M	-37.8M	-22.73M
Depreciation & Amortization	423.57K	481.01K	452.05K	471.42K	462.74K	211.39K	209.59K	269.87K	268.18K	152.1K
Stock-Based Compensation	499.87K	756.27K	1.64M	1.91M	2.65M	5.05M	11.24M	17.92M	13.64M	8.1M
Deferred Taxes	2.05M	-2.26M	630.15K	-438.06K	-1.26M	-3.57M	76.21K	177.5K	367.18K	-1.92K
Other Non-Cash Items	-8.63K	962.1K	6.13M	6.16M	19.54M	-17.38M	-1.14M	1.92M	1.62M	-15.57M
Working Capital Changes	-5.03M	7.65M	3.54M	-1.56M	-4.35M	-7.28M	25.88M	-15.15M	222.49K	0
Change in Receivables	-4.52M	7.23M	1.87M	-1.35M	-87.79K	-3.56M	4.54M	-4.15M	546.2K	-657.25K
Change in Inventory	-738.83K	-479.42K	375.04K	-1.45M	-3.3M	546.38K	-3.13M	648.63K	986.11K	863.93K
Change in Payables	-376.31K	897.47K	495.97K	-56.94K	-312.08K	597.1K	18.59M	-7.43M	-5.43M	-2.76M
Cash from Investing+	-6.37K	-90.37K	-50.65K	-108.52K	-105.76K	14.62M	4.27M	6.33M	146.21K	25.14M
Capital Expenditures	-6.37K	-133.49K	-50.65K	-108.52K	-105.76K	-376.65K	-733.05K	-665.7K	-158.32K	-1.08K
CapEx % of Revenue	0%	0.01%	0%	0%	0%	0.01%	0.02%	0.04%	0.01%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	7M	304.54K	24.75M
Cash from Financing+	0	0	12.08M	8.13M	9.33M	109.72M	1.07M	11.11M	36.83M	-4.22M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	2.72M	3.66M	0	1.64M	0	4.97M	1.66M	-4.22M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.72M	849.4K	-11.6M	-5.59M	-2.04M	-15.95M	-48.24M	-88.68M	-21.84M	-30.04M
FCF Margin %	-0.08%	0.06%	-0.73%	-0.18%	-0.05%	-0.26%	-1.23%	-5.44%	-1.29%	-
FCF Growth %	-0.02%	1.49%	-14.65%	0.52%	0.64%	-6.83%	-2.02%	-0.84%	0.75%	-0.38%
FCF per Share	-0.59	0.25	-2.15	-0.88	-0.30	-1.90	-6.02	-10.44	-1.62	-2.05
FCF Conversion (FCF/Net Income)	-4.97x	-0.15x	0.48x	0.46x	0.10x	-2.11x	0.57x	0.94x	0.57x	1.32x
Interest Paid	0	0	0	0	314.5K	8.48M	2.62M	554.82K	704.6K	0
Taxes Paid	0	0	222.22K	303.58K	362.06K	248.75K	422.13K	247.36K	368.82K	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	1.03%	-16.05%	-61.43%	-38.88%	-60.77%	8.11%	-71.27%	-181.8%	-145.4%	-89.74%
Return on Invested Capital (ROIC)	7.47%	-16.61%	-38.16%	-12.87%	-32.14%	26.18%	-200.83%	-327.6%	-121.11%	50.54%
Gross Margin	60.33%	51.4%	55.36%	68.1%	72.28%	78.24%	77.73%	46.43%	34.67%	-
Net Margin	1.56%	-48.42%	-150.89%	-37.79%	-44.55%	12.07%	-212.88%	-571.6%	-223.86%	-
Debt / Equity	-	-	0.38x	0.37x	0.47x	0.09x	0.19x	0.73x	0.43x	0.17x
Interest Coverage	0.91x	-4.16x	-7.07x	-1.37x	-3.19x	2.66x	-19.05x	-38.64x	-60.77x	-
FCF Conversion	-4.97x	-0.15x	0.48x	0.46x	0.10x	-2.11x	0.57x	0.94x	0.57x	1.32x
Revenue Growth	-32.13%	-38.29%	16.18%	100.47%	33.92%	43.83%	-35.76%	-58.59%	3.62%	-100%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Global public health sector	-	-	-	-	-	-	-	-	-	14.49M
Global public health sector Growth	-	-	-	-	-	-	-	-	-	-
U.S. prescription channel	-	-	-	-	-	-	-	-	-	2.4M
U.S. prescription channel Growth	-	-	-	-	-	-	-	-	-	-
Other Products	-	-	-	-	-	-	-	2.42K	13.01K	-
Other Products Growth	-	-	-	-	-	-	-	-	438.84%	-
Preboost	-	-	-	-	884.02K	2.04M	862.83K	-	-	-
Preboost Growth	-	-	-	-	-	130.23%	-57.61%	-	-	-
U	-	-	-	5.22M	-	-	-	-	-	-
U Growth	-	-	-	-	-	-	-	-	-	-
Other Countries	-	-	-	4.52M	-	-	-	-	-	-
Other Countries Growth	-	-	-	-	-	-	-	-	-	-
Z	-	-	-	2.16M	-	-	-	-	-	-
Z Growth	-	-	-	-	-	-	-	-	-	-
K	-	-	-	1.01M	-	-	-	-	-	-
K Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	-	-	-	5.35M
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-
Other Geographical Areas	-	-	-	-	-	-	-	-	-	4.7M
Other Geographical Areas Growth	-	-	-	-	-	-	-	-	-	-
BRAZIL	-	-	-	-	-	-	-	-	-	2.76M
BRAZIL Growth	-	-	-	-	-	-	-	-	-	-
MOZAMBIQUE	-	-	-	-	-	-	-	-	-	2.17M
MOZAMBIQUE Growth	-	-	-	-	-	-	-	-	-	-
SOUTH AFRICA	-	-	-	-	-	-	-	-	-	1.9M
SOUTH AFRICA Growth	-	-	-	-	-	-	-	-	-	-
U	2.03M	2.46M	1.29M	5.22M	17.26M	30.34M	48.94M	31.43M	-	-
U Growth	-	21.44%	-47.73%	305.28%	230.65%	75.77%	61.31%	-35.78%	-	-
Other Countries	10.71M	9.23M	6.02M	4.52M	14.54M	12.25M	12.32M	7.92M	-	-
Other Countries Growth	-	-13.77%	-34.78%	-24.98%	221.89%	-15.74%	0.54%	-35.68%	-	-
Z	2.7M	3.31M	2.23M	2.16M	-	-	-	-	-	-
Z Growth	-	22.59%	-32.62%	-3.05%	-	-	-	-	-	-
K	-	-	-	1.01M	-	-	-	-	-	-
K Growth	-	-	-	-	-	-	-	-	-	-
M	-	-	1.43M	-	-	-	-	-	-	-
M Growth	-	-	-	-	-	-	-	-	-	-
C	-	-	891K	-	-	-	-	-	-	-
C Growth	-	-	-	-	-	-	-	-	-	-
N	-	-	846K	-	-	-	-	-	-	-
N Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Veru Inc. (VERU) reported $6.7M in revenue for fiscal year 2025. This represents a 81% decrease from $35.0M in 2012.

Veru Inc. (VERU) saw revenue decline by 100.0% over the past year.

Veru Inc. (VERU) reported a net loss of $32.7M for fiscal year 2025.

Dividend & Returns

Veru Inc. (VERU) has a return on equity (ROE) of -89.7%. Negative ROE indicates the company is unprofitable.

Veru Inc. (VERU) had negative free cash flow of $29.0M in fiscal year 2025, likely due to heavy capital investments.